Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19217172 | Method of Use for Benzofuran Compounds | May 2025 | February 2026 | Allow | 8 | 1 | 1 | No | No |
| 19182382 | METHODS OF TREATING GASTROINTESTINAL INFLAMMATORY DISEASE | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19006633 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMA | December 2024 | October 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18774123 | DOSING REGIMEN FOR TREATING INFLAMMATORY BOWEL DISEASE | July 2024 | April 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18753928 | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | June 2024 | November 2025 | Allow | 17 | 3 | 1 | Yes | No |
| 18674755 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | May 2024 | November 2025 | Allow | 18 | 3 | 1 | Yes | No |
| 18626607 | CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME | April 2024 | July 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18553326 | POLYPEPTIDES TARGETING HLA-A*11 AND METHODS OF USE THEREOF | September 2023 | March 2026 | Allow | 30 | 0 | 0 | Yes | No |
| 18461190 | OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE | September 2023 | December 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18329562 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | June 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18246173 | POLYNUCLEOTIDE FOR PHYSIOLOGICAL EXPRESSION IN T-CELLS | March 2023 | January 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18067948 | CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME | December 2022 | January 2024 | Allow | 12 | 0 | 1 | No | No |
| 18001583 | ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17998733 | SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTS | November 2022 | February 2026 | Allow | 39 | 1 | 0 | No | No |
| 17917726 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17938886 | CD37-BINDING MOLECULES IMMUNOCONJUGATES THEREOF | October 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17911937 | COMBINATION TREATMENT FOR CANCER INVOLVING ANTI-ICOS AND ANTI-PD1 ANTIBODIES, OPTIONALLY FURTHER INVOLVING ANTI-TIM3 ANTIBODIES | September 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17929655 | COMBINATIONS OF IMMUNOTHERAPIES AND USES THEREOF | September 2022 | March 2025 | Abandon | 31 | 3 | 0 | Yes | No |
| 17801454 | METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17795500 | CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOF | July 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17813434 | ANTIBODY CONSTRUCTS FOR FLT3 AND CD3 | July 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17793587 | LIGAND-BINDING FUSION PROTEINS | July 2022 | March 2026 | Allow | 44 | 1 | 1 | Yes | No |
| 17780068 | POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTOR | May 2022 | February 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17745590 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES | May 2022 | November 2025 | Allow | 42 | 1 | 1 | No | No |
| 17743727 | Cysteine Engineered Antibodies and Conjugates | May 2022 | October 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17734881 | PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS | May 2022 | August 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17734253 | MULTISPECIFIC ANTIBODY CONSTRUCTS | May 2022 | July 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17770922 | NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 | April 2022 | January 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17720937 | MODIFIED ANTIBODY CONSTANT REGION | April 2022 | December 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17719894 | FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION | April 2022 | April 2025 | Allow | 36 | 0 | 1 | No | No |
| 17658731 | GLYCAN-BASED ANTIBODY-DRUG CONJUGATES | April 2022 | September 2025 | Allow | 41 | 2 | 1 | No | No |
| 17642011 | DEVICES AND METHODS FOR MODULATING ADMA IN BLOOD | March 2022 | September 2025 | Allow | 43 | 2 | 1 | No | No |
| 17689388 | CD19 BINDING AGENTS AND USES THEREOF | March 2022 | January 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17682633 | CELL SURFACE COUPLING OF NANOPARTICLES | February 2022 | May 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17680174 | Anti-CD30 monoclonal antibodies and chimeric antigen receptors | February 2022 | August 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17670718 | METHOD FOR CONTROLLING AFFINITY OF ANTIBODY FOR ANTIGEN, ANTIBODY WHOSE AFFINITY FOR ANTIGEN HAS BEEN ALTERED, AND ITS PRODUCTION METHOD | February 2022 | February 2025 | Allow | 36 | 0 | 1 | No | No |
| 17666018 | Humanized anti-DKK2 antibody and uses thereof | February 2022 | December 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17633046 | MODIFIED HUMAN VARIABLE DOMAINS | February 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17586455 | MULTISPECIFIC ANTIBODIES | January 2022 | July 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17645737 | VACCINE | December 2021 | March 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17645741 | VACCINE | December 2021 | November 2022 | Allow | 11 | 2 | 0 | Yes | No |
| 17542948 | Anti-TfR1 Antibody MAb11-22.1 Conjugates for Cancer Treatment | December 2021 | January 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17530211 | GENETICALLY MODIFIED NK-92 CELLS HAVING A SAFETY SWITCH | November 2021 | April 2025 | Allow | 40 | 2 | 1 | No | No |
| 17525512 | HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAME | November 2021 | February 2025 | Allow | 39 | 1 | 0 | No | No |
| 17522663 | IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES | November 2021 | February 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17518123 | CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF | November 2021 | November 2024 | Allow | 37 | 1 | 0 | No | No |
| 17515250 | PD-1-CD28 FUSION PROTEINS AND THEIR USE IN MEDICINE | October 2021 | November 2025 | Allow | 49 | 2 | 1 | No | No |
| 17488698 | METHOD FOR GENERATING AVID-BINDING MULTISPECIFIC ANTIBODIES | September 2021 | July 2025 | Allow | 45 | 1 | 0 | Yes | No |
| 17479930 | Combination Therapy for the Treatment of Cancer | September 2021 | January 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17433155 | Novel Fusion Proteins Specific for CD137 and GPC3 | August 2021 | July 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17405104 | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) IMMUNOADHESIN MICROBODY | August 2021 | February 2024 | Allow | 30 | 0 | 1 | Yes | No |
| 17431664 | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner | August 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17383765 | Anti-Abeta Antibodies | July 2021 | June 2025 | Allow | 46 | 3 | 1 | Yes | No |
| 17305577 | FUSION CONSTRUCTS AND METHODS OF USING THEREOF | July 2021 | August 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17351724 | Combination Therapy for the Treatment of Cancer | June 2021 | May 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17342518 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof | June 2021 | August 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17328118 | CD70 Binding Molecules and Methods of Use Thereof | May 2021 | August 2024 | Allow | 39 | 1 | 1 | No | No |
| 17318590 | CELL SURFACE COUPLING OF NANOPARTICLES | May 2021 | October 2021 | Allow | 5 | 0 | 0 | No | No |
| 17317824 | AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAME | May 2021 | November 2024 | Allow | 42 | 0 | 1 | Yes | No |
| 17307158 | COMPOSITIONS AND METHODS FOR TREATING CANCER | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17235805 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | April 2021 | August 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17285836 | PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAME | April 2021 | November 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 17227536 | Tetravalent Antibody-Drug Conjugates and Use Thereof | April 2021 | December 2023 | Allow | 32 | 0 | 0 | Yes | No |
| 17217839 | GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCER | March 2021 | August 2021 | Allow | 5 | 1 | 0 | No | No |
| 17279775 | METHODS OF SELECTING TREATMENT FOR CXCR4-ASSOCIATED CANCER | March 2021 | August 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17210124 | Antibodies Targeted to Fungal Cell Wall Polysaccharides | March 2021 | November 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17278075 | METHODS OF REVERSING TICAGRELOR ACTIVITY | March 2021 | November 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17200322 | EGFR-DIRECTED CAR THERAPY FOR GLIOBLASTOMA | March 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17200287 | MATERIALS AND METHODS FOR MODULATING DELTA CHAIN MEDIATED IMMUNITY | March 2021 | January 2026 | Abandon | 58 | 4 | 1 | No | No |
| 17198179 | ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF | March 2021 | June 2024 | Allow | 39 | 1 | 1 | No | No |
| 17176858 | METHOD FOR ENGINEERING IMMUNOGLOBULINS | February 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17268174 | CANCER STEM CELL MARKER AND CANCER STEM CELL TARGETING DRUG | February 2021 | April 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17172694 | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF | February 2021 | May 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17172698 | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF | February 2021 | October 2025 | Allow | 57 | 3 | 1 | No | Yes |
| 17172700 | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF | February 2021 | January 2025 | Allow | 48 | 1 | 1 | No | No |
| 17168100 | CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF | February 2021 | October 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 17264735 | MULTISPECIFIC TREG BINDING MOLECULES | January 2021 | October 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17151911 | BIOLOGICAL PRODUCTS | January 2021 | December 2023 | Abandon | 34 | 1 | 0 | No | No |
| 17150272 | B CELL MATURATION ANTIGEN BINDING PROTEINS | January 2021 | January 2024 | Allow | 36 | 1 | 1 | No | No |
| 17150626 | PRO-ANTIBODY THAT REDUCES OFF-TARGET TOXICITY | January 2021 | November 2025 | Allow | 58 | 3 | 1 | Yes | No |
| 17148337 | MULTISPECIFIC TREG BINDING MOLECULES | January 2021 | April 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17121622 | Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods | December 2020 | November 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16972319 | COMPLEMENT C4D ASSAY | December 2020 | February 2026 | Abandon | 60 | 3 | 1 | No | No |
| 17112206 | METHODS FOR PREVENTING ACUTE KIDNEY INJURY | December 2020 | September 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 17104983 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | November 2020 | July 2024 | Allow | 44 | 2 | 2 | Yes | No |
| 17103190 | USE OF HEXOKINASE-2 IN DETECTION OF RARE TUMOR CELLS IN BODY FLUID SAMPLE AND KIT | November 2020 | October 2021 | Allow | 10 | 2 | 1 | No | No |
| 17096513 | METHODS OF ASSESSING AND TREATING CANCER IN SUBJECTS HAVING DYSREGULATED LYMPHATIC SYSTEMS | November 2020 | July 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17051731 | METHODS AND SYSTEMS FOR SELECTION AND TREATMENT OF PATIENTS WITH INFLAMMATORY DISEASES | October 2020 | November 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 17084156 | THERAPEUTIC CD47 ANTIBODIES | October 2020 | October 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17078903 | TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR | October 2020 | January 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17048739 | Switch Molecule And Switchable Chimeric Antigen Receptor | October 2020 | January 2024 | Allow | 39 | 4 | 1 | Yes | No |
| 17032482 | DISRUPTION OF THE WAVE3 PROTEIN COMPLEX FOR SUPPRESSION OF INVASION AND METASTASIS | September 2020 | May 2023 | Allow | 32 | 0 | 1 | Yes | No |
| 17040426 | COMBINATION OF NEAR INFRARED PHOTOIMMUNOTHERAPY TARGETING CANCER CELLS AND HOST-IMMUNE ACTIVATION | September 2020 | January 2025 | Abandon | 52 | 3 | 1 | No | No |
| 16982723 | FC VARIANT COMPOSITIONS AND METHODS OF USE THEREOF | September 2020 | February 2024 | Abandon | 41 | 3 | 1 | Yes | No |
| 17025980 | PRODUCTION OF HETEROMULTIMERIC PROTEINS | September 2020 | June 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17023835 | Modified Cell with Enhanced Functionality and Cellular Therapy thereof | September 2020 | July 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17021423 | Anti-MET Antibodies and Methods of Use Thereof | September 2020 | September 2023 | Allow | 36 | 1 | 1 | No | No |
| 16980730 | MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF | September 2020 | June 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16980816 | BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY | September 2020 | May 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16994795 | ANTI-MICA ANTIGEN BINDING FRAGMENTS, FUSION MOLECULES, CELLS WHICH EXPRESS AND METHODS OF USING | August 2020 | August 2023 | Allow | 36 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DUFFY, BRADLEY.
With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DUFFY, BRADLEY works in Art Unit 1643 and has examined 944 patent applications in our dataset. With an allowance rate of 51.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner DUFFY, BRADLEY's allowance rate of 51.9% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DUFFY, BRADLEY receive 1.82 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by DUFFY, BRADLEY is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +54.2% benefit to allowance rate for applications examined by DUFFY, BRADLEY. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 35.6% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 84.4% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 65.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 59.5% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.2% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.3% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.